News
Asarina Pharma AB: new US CDC study suggests prevalence of Tourette significantly higher than previously thought
2022-09-05 13:24
A new study – ‘Estimating the number of people with Tourette syndrome and persistent tic disorder in the United States’ - has been published...
Asarina Pharma AB (publ) Q2 2022 Report released
2022-08-25 08:30
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME CEO Peter Nordkild: “If full clinical development is successful, Sepranolone will be the...
Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen
2022-06-23 11:15
On 31 May 2021, Asarina Pharma announced by press release that the Company had signed a convertible loan agreement with ÖSS (the “Loan Agreement”)...
Asarina Pharma AB (publ) Q1 2022 Report released
2022-05-25 08:30
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/...
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
2022-05-04 11:29
Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2021...
ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED
2022-04-06 17:25
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS FEBRUARY 11: Prof. Marco Bortolato (Univ. of Utah, USA) presents two sets of new preclinical data confirming that...
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ)
2022-04-05 08:00
Asarina Pharma’s Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting...
Asarina Pharma AB (publ) Year-end Report 2021 released
2022-02-24 08:00
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME The Capital Region of Denmark (Region Hovedstaden) was finally able to sign the clinical trial...
First patient in for landmark Tourette Syndrome study
2022-02-16 14:31
30 patients ranging from 12 to 45 years old will be taking part in a phase IIa proof-of-concept study at two major University Hospitals in Copenhagen -...
The phase IIa Tourette study will take place at the Danish National Center for Tourette at Herlev University Hospital, Scandinavia’s largest Tourette...